Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.
Adrenocortical carcinoma (ACC) is a rare but aggressive tumor entity with overall poor prognosis (1-1 4) . Response to medical treatment is limited and only recently the first randomized trial in patients 2 with advanced disease established doxorubicin, etoposide, cisplatin plus mitotane as first-line 3 cytotoxic therapy (5) . However, this trial also demonstrated the limitations of systemic treatment 4 with a median overall survival of only 15 months highlighting the importance of early diagnosis and 5 appropriate initial treatment. Although strategies of surgical resection such as open or laparoscopic 6 approaches are controversial (6) (7) (8) , surgery is the mainstay of initial ACC therapy and currently 7 provides the only realistic chance for cure of the disease. However, even after complete resection 8 patients with ACC remain at high risk for recurrence. 9
As a response to this clinical challenge adjuvant treatment with mitotane is frequently 10 recommended (2, 9) . Although mitotane has shown significant efficacy in preventing recurrence in 11 this setting (10) , it has a wide range of side effects and impacts hormone (11) (12) (13) and drug (14) 12 metabolism. An additional adjuvant measure is irradiation of the tumor bed, for which some (15, 16) 13 but not all (17) studies have demonstrated efficacy in preventing local recurrence but not to prolong 14 recurrence-free survival (RFS) or overall survival (OS). Thus, all current treatment concepts have the 15 disadvantages of uncertain efficacy and significant toxicity. Therefore, it would be of major 16 importance to limit these treatments to patients with high risk of recurrence which is highly variable 17 in ACC patients (1, (18) (19) (20) (21) . 18 While histopathological scores are in use to differentiate between benign and malignant adrenal 19 neoplasms they have not been investigated for their prognostic value. Recently, a number of 20 molecular markers have been identified that were correlated with clinical outcome (22) and even had 21 predictive value for treatment response (23, 24) . However, the majority of applied techniques require 22 fresh frozen tumor material and none of these markers has been evaluated in a large patient cohort. 23
Therefore, we set out to identify prognostic factors from routine diagnostic work-up to provide 24 guidance for adjuvant therapy after radical resection. For this purpose we took advantage of large 25 cohorts of ACC patients with detailed clinical and histopathological annotations within the European 1 network for the study of adrenal tumors (ENSAT). 2 3
Patients and Methods 1

Patient selection 2
Patients diagnosed with ACC between 1979 and 2011 were identified from the German ACC 3 registry that fulfilled the following inclusion criteria: histologically proven ACC, and 4 localized disease (ENSAT stage I-III(18)) after R0 resection. Resection status was judged on 5 the basis of surgical and pathology reports. Furthermore, a minimum follow-up of 12 months 6 was mandatory unless death occurred earlier. Two third of tumor samples of the German 7 cohort were reviewed by the national reference pathologist (W.S.). All items required to 8 calculate the scores suggested by Weiss, van Slooten, and Hough as well as 9 immunohistochemical staining for Mib1 (Ki67) were evaluated. Further clinical information 10 included in the analysis are provided in Table 1+2 . Mitotane therapy was defined as adjuvant 11 therapy with mitotane within 3 months following surgery; hormone production was recorded 12 as any biochemically proven adrenocortical hormone excess. 13 As an independent validation cohort patients from three European countries were identified 14 from the ENSAT ACC registry based on the same inclusion criteria as stated above. Within 15 this cohort a subset of pre-defined clinical parameters such as age, sex, ENSAT stage (tumor 16 size, lymph node status and VTT), endocrine activity of the tumor and adjuvant mitotane 17 therapy as well as Ki67 were analyzed. 18 Both registries had been approved by the local ethics committees of all partaking centers and all 19 included patients had provided written informed consent. 20
21
Outcome definitions and statistical analysis 22
The pre-specified primary endpoint of the study was RFS, which was defined as the time interval 23 between initial surgery and the date of radiologic evidence of disease relapse, death resulting from 24 any cause or the date of last follow-up. As a secondary endpoint OS was calculated from the date of 1 first surgery to death from any cause or the last follow-up visit. RFS and OS rates over time from 2 initial surgery were estimated using the Kaplan-Meier method. The significance of the demographic 3 parameters and clinical characteristics for prognosis of RFS and OS was determined by univariable 4 and multivariable Cox regression models. As the lowest category for Ki67 <5% and for tumor size 5 <5cm was set. 6
As for the diagnostic scores different strategies were applied to take into account limitations of 7 individual residual analyses. Indeed, following an exploratory analysis model construction was based 8 on stepwise, forward and backward selection using p-value criteria in the range between 0.05 and 9 0.25. Tumor size was explored as a continuous factor and according to cut-off values. Potential cut-10 off values for tumor size were pre-specified at 5cm, 8cm, 11cm, 15cm, and 20cm. Furthermore, the 11 number of factors included, the score statistic, the contribution to the change of the hazard in the 12
Cox-model as well as differentiation of survival curve estimation by use of the predictor were 13 considered. Martingale residual analysis was performed indicating well fitting with continuous Ki67 14 and exploring grouping by equidistant increases of 5% or of 10%. Extensive sensitivity analyses with 15 multivariable models including, excluding and exchanging potential factors from the first explored 16 models were performed. Comparisons between groups were conducted applying the log rank test 17 and presenting two-sided p-values. Estimates of median times to event and hazard ratios (HR) are 18 provided with 95% confidence intervals (CI). 19 20 21
Results 1
Patient cohorts and characteristics 2
A total of 319 patients from the German registry and additional 250 patients from 7 European 3 centers fulfilled the pre-specified inclusion criteria. Patient characteristics at initial diagnosis 4 are summarized in Table 1 . While tumor stage and most of other clinical items were not 5 different between the groups, the percentage of patients on adjuvant mitotane treatment was 6 significantly lower in the German cohort (26.3 vs. 64.8%). 
German cohort 9
Univariable analyses for all presumably relevant demographic, clinical, and histopathological 10 parameters were performed ( Table 2 ). None of the clinical parameters showed significant correlation 11 with both RFS and OS. Tumor stage was of prognostic value but the discrimination was not found to 12 be sufficient for clinical guidance on adjuvant therapeutic strategies ( Supplementary Figure 1 ). 13
Within the large set of histological parameters only few were associated with poor clinical outcome 14 (Table 2 ) and several multi-item scores were not able to predict outcome better than individual 15 parameters. In contrast, the proliferation marker Ki67 was found to be the single most relevant 16 predictor of disease recurrence and survival with an hazard ratio of 1.042 per 1% increase of Ki67 17 index for recurrence (p<0.0001) and 1.051 for death (p<0.0001), respectively ( Figure 1A+C ). 23
Upon a stepwise and a backward multivariable analysis involving all parameters with a p-value of 24 <0.15 in the univariable analysis plus adjuvant mitotane therapy and taking into account sensitivity 25 analyses and regression diagnostics, Ki67 remained the factor with the best prognostic power with a 1 hazard ratio of 1.046 per 1% for RFS and 1.061 per 1% for OS ( relevance when the analysis was adjusted for Ki67. While age, tumor size, and VTT had some 6 association with clinical outcome none of these factors showed a similar prognostic power for both 7 RFS and OS as Ki67. 8
Of note, adjuvant treatment with mitotane was not significantly associated with clinical outcome in 9 univariable analysis, but after multivariable adjustment a trend for longer RFS was detectable (HR 10 0.71; p=0.087) and it became a significant factor for OS (HR 0.41; p=0.009, Table 4 ). 11
12
European validation cohort 13
Following these observations we investigated a defined sub-set of clinical and histopathological 14 parameters within the European validation cohort. Comparable to the German cohort the 15 proliferation marker Ki67 provided the best prognostic value for prediction of RFS and OS, 16 respectively ( Table 3 and Figure 1B+D ). Following multivariable analysis Ki67 retained highly 17 significant association with RFS and OS with a hazard ratio for recurrence of 1.020 [1.010-1.029] and 18 for overall survival of 1.026 [1.013-1.039] per 1% increase, respectively (Table 4 ). Similar to the 19 German cohort, age tumor size and the presence of VTT harbored none or only minor prognostic 20 value (Table 4 ). 21
22
Establishment of a prognostic score 23
In a next step, we aimed at the development of a prognostic score for further clinical guidance in the 1 management of patients with ACC after complete resection. For this purpose, we applied two 2 different models using the pooled data of both cohorts (n=569). Both algorithms included the 3 following 3 risk factors (RF): Ki67, tumor size between 15 and 20 cm and presence of VTT. 4
In the first, basic model Ki67 was regarded as one RF for Ki67≥10% and as a second RF for Ki67≥20%. 5
Either tumor size of 15-20cm or presence of VTT was accounted as one combined RF. Each of these 3 6 RF was counted as 1 point in the prognostic score, which resulted in 4 groups (0-3 RF) with different 7 outcome. However, applying this score, estimated RFS and OS of the different risk groups by Kaplan-8
Meier analysis provided no clinically meaningful separation between the two groups with the highest 9 scores which were therefore combined ( Figure 2B, Supplementary Figure 2B ). In the next model the 10 same RF were weighted individually according to their prognostic power and specifically for RFS. This 11 second modeling resulted in a slightly improved risk prediction and allowed for differentiation in 12 more subgroups ( Figure 2C, Supplementary Figure 2C ). 13
Discussion 1
This largest study on prognostic factors in localized ACC provides strong evidence that Ki67 index is 2 the most powerful tool of all parameters analyzed in this study to predict recurrence in two 3 independent cohorts of patients after complete surgical resection. Likewise, OS was also strongly 4 associated with the Ki67 index. Following multivariable analysis including age, tumor stage, adjuvant 5 mitotane treatment and all standard histological parameter used in ACC, the Ki67 index retained its 6 outstanding prognostic power. Importantly, these results initially obtained from a German cohort 7 could be validated in an independent European sample. In a next step, we aimed at the 8 establishment of clinical risk scores. Although both applied models including the parameters Ki67, 9
tumor size, and presence of VTT were able to discriminate patient cohorts with different clinical 10 outcome, the added value of these scores in comparison to the use of Ki67 alone was modest. Thus, 11
Ki67 is obviously the best factor to establish a grading system in ACC with Ki67 <10% defining grade 1 12 tumors, Ki67 10-19% grade 2 and Ki67 ≥20% grade 3 tumors. 13
14
ENSAT stage III has been defined by the presence of positive lymph nodes, tumor infiltration in 15 surrounding tissue or the presence of VTT, while stage IV is restricted to patients with distant 16 metastasis (18) . This system which had been independently validated (25) performs well over the 17 whole spectrum of ACC patients to predict overall prognosis. However, as we demonstrate herein 18 within the pre-selected patient group with localized disease following complete surgical resection the 19
ENSAT staging system seems to be of limited relevance. The reason for this lack of prognostic power 20 is most likely due to the fact that stage III usually comes with a relatively high risk of incomplete 21 resection. In fact, according to a German (26) and an U.S. series (20) this accounts for about 10% of 22 patients with localized ACC. However, these cases as well as those with uncertain resection status 23 were excluded from our analysis, because the high risk for recurrence in these patients is obvious. 24
Another initially surprising result is the fact that the outcome of patients with a tumor size >20 cm 1 was better than of those with smaller tumors. However, as described above, this series is a highly 2 selected cohort and very large tumors that are still resectable and not metastasized at the time of 3 surgery might indeed represent a subgroup of tumors with specific biological behavior. 4
To appreciate the quite variable outcome even in the well defined subgroup of completely resected 5 patients, additional parameters with prognostic value need to be taken into consideration. Recently, 6
inclusion of tumor grading on the basis of mitotic counts has been proposed to improve the 7 prediction of prognosis (27) . Accordingly, in our two independent cohorts, quantification of Ki67 as a 8 well defined marker of cellular proliferation provided additional prognostic information with relevant 9 clinical impact. This is in good agreement with earlier studies which had suggested Ki67 as a marker 10 with prognostic value in ACC patients (28) (29) (30) (31) . While these series were small and the overall results 11 therefore not consistent, based on the current results, we strongly suggest tumor grading based on 12 three categories of a Ki67 index <10%, 10-19% and above 20%. 13
Ki67 index in our analysis proved to be superior to different histological scores such as those 15
proposed by Weiss, van Slooten or Hough that are currently in clinical use for the differential 16 diagnosis of adrenal tumors. The reason for this finding probably relates to the fact that a number of 17 sub-items required for these scores such as atypical mitoses, abnormal nucleoli and nuclear atypia 18 had no prognostic potential or were even associated with a trend towards better outcome. This does 19 not question the overall applicability of the scores to discern between benign adrenal adenomas and 20 ACC for which purpose they had been originally proposed. However, the findings highlight the 21 limitation of the scores as prognostic tools for this particular group of patients and fuels speculation 22 whether these sub-items are of particular importance for the scores. Along the same line, some 23 pathologists have argued for a simplified Weiss score that bases on the more reliable criteria only (32, 24 33) . 25 1
The effect of mitotane on clinical outcome was surprisingly different between the German cohort 2 and the validation cohort. Due to the retrospective nature of our study we can only speculate about 3 the underlying reasons for this difference. However, the fact that in the German series only 84 out of 4 319 patients (26%) were treated with mitotane in comparison to 65% in the validation series already 5 point towards a general difference in therapeutic policies. One explanation for this discrepancy is 6 probably related to the time interval of patient inclusion. Two third of the German patients were 7 diagnosed before 2007, when the land-mark study on the adjuvant usage of mitotane had been 8 published(10), whereas the non-German cohorts were recruited mostly after that time period. 9
However, this observation could also be interpreted as another hint that not all patients will benefit 10 from mitotane treatment and prospective trials are required to provide reliable answers. 11
12
In variance to recent studies in the current cohort no relevant adverse effect of steroid excess on RFS 13 and OS was found. One of the differences that are present in the current publications refer to the 14 cohorts. While in a recent manuscript by Berruti and colleagues (34) some overlap with our study is 15 present adding patients from North America might have contributed to the observed differences. In 16 fact, in two studies from single US centers (35, 36) both find Cushing's syndrome as a marker of poor 17
prognosis. In addition -and probably more importantly -while in our study hormone excess was 18 defined by biochemical means, in the published studies this was judged on a clinical basis. 19 20 Our study has obvious limitations as a result of its non-randomized design, in which multiple factors 21 may have led to different treatment decisions in individual patients. These limitations are shared by 22 other studies that have investigated prognostic factors in ACC patients (for details see Suppl. Table  23 1). Furthermore, variability of Ki67 index evaluation at different clinical centers is to be expected. 24
This refers to pre-analytic variations, usage of different antibodies and staining reagents as well as 1 quantification underestimating tumor heterogeneity. 
Conclusions 14
In conclusion, in this study analyzing multiple potential prognostic markers in two independent 15 cohorts of 568 patients with completely resected ACC Ki67 emerged as the single most important 16 factor predicting recurrence and should be part of any pathology report of ACC to provide tumor 17 grade. This finding will further guide the management of patients with this rare disease. 
